If you or a loved one has an IMMUNE DEFICIENCY, you might qualify for a trial and receive a new, investigational product at no cost.
Research is at the heart of advancing our knowledge of IMMUNE DEFICIENCIES
Without people like you, we would not be where we are today.
About the study
The purpose of this study is to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
To learn more about the study and see if you qualify, call today.